TY - JOUR
T1 - Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma
T2 - Efficacy and safety of radiofrequency ablation and cryoablation therapy
AU - McBride, Jeremy F.
AU - Atwell, Thomas D.
AU - Charboneau, William J.
AU - Young, William F.
AU - Wass, Thomas C.
AU - Callstrom, Matthew R.
N1 - Funding Information:
M.R.C. received a research grant from Seimens Medical Systems . None of the other authors have identified a conflict of interest.
PY - 2011/9
Y1 - 2011/9
N2 - Purpose: To evaluate the safety and efficacy of percutaneous ablation methods for the treatment of metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs). Materials and Methods: From May 2001 to November 2009, 10 patients (mean age 45 years) with metastatic PCCs and PGLs were identified and treated with percutaneous ablation. All patients were given appropriate medication before the ablation procedure. Vital signs were monitored before, during, and after the procedure. There were 47 tumor ablations performed using radiofrequency (RF) ablation, cryoablation, or ethanol injection as determined by tumor location. Results: In all patients, all metastatic lesions amendable to percutaneous ablation were treated; for 2 of 10 patients, all known metastases were treated. Successful ablation without evidence of recurrence was achieved in 56% (15 of 27) of primarily treated lesions in patients with available follow-up imaging. The time to disease progression after ablation was 7.2 months ± 4.0. Amelioration of breakthrough hypertensive symptoms or metastasis-related pain was achieved in two of two patients and four of four patients, respectively, at clinical follow-up. Comparison of intra-arterial blood pressure before, during, and after the procedures showed statistically significant differences in these median blood pressures (P =.004.05). Major complications occurred after 2 of 18 (11%) ablation sessions, including one unplanned increase in level of patient care and one periprocedural death from complications related to bowel perforation. Conclusions: Local control of metastatic PCCs and PGLs with percutaneous ablation can play an important role in disease management when the lesions are unresectable surgically, and there is potential for prolongation of patient function or amelioration of metastasis-related symptoms.
AB - Purpose: To evaluate the safety and efficacy of percutaneous ablation methods for the treatment of metastatic pheochromocytomas (PCCs) and paragangliomas (PGLs). Materials and Methods: From May 2001 to November 2009, 10 patients (mean age 45 years) with metastatic PCCs and PGLs were identified and treated with percutaneous ablation. All patients were given appropriate medication before the ablation procedure. Vital signs were monitored before, during, and after the procedure. There were 47 tumor ablations performed using radiofrequency (RF) ablation, cryoablation, or ethanol injection as determined by tumor location. Results: In all patients, all metastatic lesions amendable to percutaneous ablation were treated; for 2 of 10 patients, all known metastases were treated. Successful ablation without evidence of recurrence was achieved in 56% (15 of 27) of primarily treated lesions in patients with available follow-up imaging. The time to disease progression after ablation was 7.2 months ± 4.0. Amelioration of breakthrough hypertensive symptoms or metastasis-related pain was achieved in two of two patients and four of four patients, respectively, at clinical follow-up. Comparison of intra-arterial blood pressure before, during, and after the procedures showed statistically significant differences in these median blood pressures (P =.004.05). Major complications occurred after 2 of 18 (11%) ablation sessions, including one unplanned increase in level of patient care and one periprocedural death from complications related to bowel perforation. Conclusions: Local control of metastatic PCCs and PGLs with percutaneous ablation can play an important role in disease management when the lesions are unresectable surgically, and there is potential for prolongation of patient function or amelioration of metastasis-related symptoms.
KW - PACU
KW - PCC
KW - PGL
KW - SD
KW - paraganglioma
KW - pheochromocytoma
KW - postanesthesia care unit
KW - standard deviation
UR - http://www.scopus.com/inward/record.url?scp=80051975164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051975164&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2011.06.016
DO - 10.1016/j.jvir.2011.06.016
M3 - Article
C2 - 21856504
AN - SCOPUS:80051975164
SN - 1051-0443
VL - 22
SP - 1263
EP - 1270
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 9
ER -